secwatch.observer — SEC 8-K summary
======================================

Issuer:     EVOME MEDICAL TECHNOLOGIES INC. (—)
CIK:        0001617765
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0001062993-24-001181
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evome Medical (fka Salona Global) changes name, reports Q3 revenue up 18.5% QoQ and positive Adj. EBITDA
--------------------------------------------------------------------------------

- Company renamed Evome Medical Technologies Inc., ticker EVMT effective Jan 22, 2024.
- Director Leslie Cross resigned effective Jan 17, 2024; no disagreement disclosed.
- Q3 FY2023 (Sep 30): revenue +18.5% QoQ, gross profit +29% QoQ, positive Adj. EBITDA of $749,425.
- Reduced Biodex acquisition debt by $428,237 in Q3; balance extended to July 2025.
- Plans to launch two new Biodex products (SpaceTek Knee, Reactive Step Trainer) into private PT market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617765/000106299324001181/0001062993-24-001181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617765/000106299324001181/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-24-001181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer